Core Insights - Prestige Consumer Healthcare Inc. reported strong financial results for the fourth quarter and fiscal year ended March 31, 2025, with record sales driven by international business strength and eCommerce growth [2][3][6] - The company achieved a 7.0% increase in fourth-quarter revenues to $296.5 million compared to $277.0 million in the same quarter of the previous year, with a 7.9% organic revenue growth [3][8] - Fiscal year 2025 revenues totaled $1,137.8 million, reflecting a 1.1% increase from $1,125.4 million in fiscal year 2024, with notable growth in the Gastrointestinal category [6][7] Financial Performance - Fourth-quarter net income was reported at $50.1 million, up from $49.5 million in the prior year, with diluted earnings per share (EPS) of $1.00 compared to $0.98 [4][7] - For fiscal year 2025, net income reached $214.6 million, an increase from $209.3 million in the previous year, with diluted EPS of $4.29 compared to $4.17 [7][8] - Non-GAAP adjusted net income for the fourth quarter was $65.9 million, up from $51.4 million in the prior year, leading to an adjusted diluted EPS of $1.32 compared to $1.02 [4][8] Segment Performance - North American OTC Healthcare segment revenues for the fourth quarter were $248.9 million, a 7.7% increase from $231.1 million in the prior year, driven by growth in GI and Women's Health categories [13][14] - International OTC Healthcare segment revenues for the fourth quarter were $47.6 million, a 3.7% increase from $45.9 million in the prior year, with strong performance from the Hydralyte brand [15][16] Cash Flow and Capital Allocation - The company generated $61.8 million in net cash from operating activities in the fourth quarter, down from $66.9 million in the prior year, with non-GAAP free cash flow of $58.4 million compared to $63.8 million [10][11] - For fiscal year 2025, net cash provided by operating activities was $251.5 million, slightly up from $248.9 million in the previous year, with non-GAAP free cash flow increasing by 1.6% to $243.3 million [11][12] Outlook - The company anticipates organic revenue growth of approximately 1% to 2% and diluted EPS in the range of $4.70 to $4.82 for fiscal year 2026, despite facing inflationary pressures from tariffs [17][18] - The initial revenue outlook for fiscal 2026 is projected between $1,140 million and $1,155 million, with free cash flow expected to exceed $245 million [18]

Core Insights - Prestige Consumer Healthcare Inc. reported strong financial results for the fourth quarter and fiscal year ended March 31, 2025, with record sales driven by international business strength and eCommerce growth [2][3][6]. Financial Performance - Fourth quarter revenues reached $296.5 million, a 7.0% increase from $277.0 million in the same quarter of the previous year, with a 7.9% increase when excluding foreign currency impacts [3][6]. - Fiscal year 2025 revenues totaled $1,137.8 million, up 1.1% from $1,125.4 million in fiscal year 2024, with a 1.2% increase excluding foreign currency effects [6][7]. - Net income for the fourth quarter was $50.1 million, compared to $49.5 million in the prior year, while diluted earnings per share (EPS) increased to $1.00 from $0.98 [4][7]. - For fiscal year 2025, reported net income was $214.6 million, up from $209.3 million, with diluted EPS rising to $4.29 from $4.17 [7][8]. Segment Performance - North American OTC Healthcare segment revenues for Q4 were $248.9 million, a 7.7% increase from $231.1 million in the prior year, driven by growth in GI and Women's Health categories [13][14]. - International OTC Healthcare segment revenues for Q4 were $47.6 million, a 3.7% increase from $45.9 million, with significant growth attributed to the Hydralyte brand [15][16]. Cash Flow and Capital Allocation - The company generated $61.8 million in net cash from operating activities in Q4, down from $66.9 million in the prior year, while non-GAAP free cash flow was $58.4 million, a decrease from $63.8 million [10][11]. - For the fiscal year, net cash provided by operating activities was $251.5 million, slightly up from $248.9 million, with non-GAAP free cash flow increasing by 1.6% to $243.3 million [11][12]. Shareholder Returns and Debt Management - The company repurchased approximately 0.7 million shares for about $51.5 million during fiscal 2025, reducing net debt to approximately $0.9 billion, resulting in a leverage ratio of 2.4x [12][18]. - The company plans to maintain a disciplined capital allocation approach, focusing on share repurchases, M&A, and deleveraging [2][8]. Fiscal 2026 Outlook - The company anticipates organic revenue growth of approximately 1% to 2% and diluted EPS in the range of $4.70 to $4.82 for fiscal 2026, despite facing inflationary headwinds from tariffs [17][18].